Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Completed Not applicable Interventional Results available

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study

NCT06350461
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Discontinuation of hypertonic saline (HS), Continuation of hypertonic saline (HS)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 7, 2026, 2:46 AM EDT
Withdrawn Not applicable Interventional

Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients

NCT01229553
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
decolonization
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
2 Months to 23 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Not applicable Interventional

PACE CF, a 3-session Mind-body Pain Management Program for Adults With Cystic Fibrosis

NCT06606457
View directory record Official record
Conditions
Cystic Fibrosis (CF), Pain Management
Interventions
Pain Acknowledgment Coping and Empowerment in CF (PACE CF)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis

NCT00006280
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin for Inhalation
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 5 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
9
States / cities
Palo Alto, California • Denver, Colorado • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 7, 2026, 2:46 AM EDT
Not listed No phase listed Observational

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis

NCT01543620
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Minneapolis, Minnesota • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Not applicable Interventional

Telehealth Cognitive Behavioral Stress Management for Adults With Cystic Fibrosis

NCT03560726
View directory record Official record
Conditions
Anxiety, Depression, Stress, Coping Skills, Cystic Fibrosis
Interventions
Cognitive Behavioral Stress Management
Behavioral
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 7, 2026, 2:46 AM EDT
Completed No phase listed Observational

Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

NCT03771313
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ceftaroline
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 7, 2026, 2:46 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

NCT04853368
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Mobile, Alabama • Los Angeles, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

NCT05033080
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

NCT00388505
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin Inhalation Powder, Tobramycin Solution for Inhalation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
24
States / cities
Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 7, 2026, 2:46 AM EDT
Completed No phase listed Observational

Cough-Generated Aerosols of NTM in Cystic Fibrosis

NCT01815866
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CF with culturable NTM
Procedure
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Results available

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

NCT02564354
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
QR-010
Drug
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Denver, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

NCT00322868
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
pioglitazone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis

NCT01355796
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Xylitol, Hypertonic saline
Drug
Lead sponsor
Joseph Zabner
Other
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 7, 2026, 2:46 AM EDT
Not yet recruiting Phase 2 Interventional

Verapamil Effect in Cystic Fibrosis-related Dysglycemia

NCT07688070
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
Interventions
Verapamil Hydrochloride
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 7, 2026, 2:46 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

A Study in Pediatric Patients With Cystic Fibrosis Lung Disease

NCT00130182
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
denufosol tetrasodium (INS37217)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 7 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Denver, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Digitoxin to Treat Cystic Fibrosis

NCT00782288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
digitoxin, placebo
Drug · Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 7, 2026, 2:46 AM EDT
Terminated Phase 3 Interventional

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

NCT00125346
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin Inhalation Powder
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 21 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 7, 2026, 2:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Not applicable Interventional

Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis

NCT00788138
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 7, 2026, 2:46 AM EDT
Completed No phase listed Observational

Molecular Phenotypes for Cystic Fibrosis Lung Disease

NCT01116414
View directory record Official record
Conditions
Cystic Fibrosis, Lung Diseases
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 7, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Cystic Fibrosis Core Strengthening and Respiratory Exercise Program

NCT00751647
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Physical Therapy
Other
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
10 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 7, 2026, 2:46 AM EDT
Active, not recruiting Phase 3 Interventional

Assessing Tenapanor as a Treatment of CF-related Constipation.

NCT06810167
View directory record Official record
Conditions
Cystic Fibrosis, Constipation
Interventions
Tenapanor
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 7, 2026, 2:46 AM EDT